Experts to discuss the patented chemical imaging technology at DDL 20 meeting

NewsGuard 100/100 Score

In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.

Obtaining drug particle size information in respiratory products is important to understand the deliverable drug load, respirable fraction, and overall quality as well as from a cost perspective. Prior to entering clinical trials, this additional data can provide invaluable information, raising confidence and lowering risk of failure in vivo biostudies. The value and importance of gaining this information before taking the expensive step of beginning clinical development cannot be emphasized enough.

"We are excited to be able to provide our customers with information that can both improve the quality of their respiratory products as well as save them time and money in the long run," said Dr. Thomas Voigt, Executive Vice President of ChemImage Corporation.

The technique uses ChemImage's unique technology combination of Raman chemical imaging, optical microscopy, and semi-automated data gathering and analysis software to identify particles based on their unique chemistry (for example, active pharmaceutical ingredient(s) versus excipients) as well as to analyze the particle size distribution in one step. Chemical information is based on the component chemistry identified by the unique Raman signature. This technique addresses the need for a fundamental understanding of API particles in the presence of other undissolved excipients in the formulation and can be used to study ISPS, aggregation and dispersion characteristics.

"We see a growing trend in the pharmaceutical industry of orally inhaled and nasal drug products with more than one active pharmaceutical ingredient," said Dr. Voigt. "In this case, morphological indications will not be enough to identify chemistry of particles in these formulations. Raman chemical imaging provides a much more objective method for ingredient-specific particle sizing."

As one of the premier meeting venues for the inhalation community, DDL provides an avenue for ChemImage to interface with researchers and business representatives regarding their product development challenges. ChemImage will be available at booth #9 to discuss chemical imaging product and service offerings.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Feeling lonely? It may affect how your brain reacts to food, new research suggests